.Clinical trial information: NCT0236259
Final analysis of overall survival (OS) and relapse-free-survival (RFS) in the intergroup S1404 phase III randomized trial comparing either high-dose interferon (HDI) or ipilimumab to pembrolizumab in patients with high-risk resected melanoma.
ATI-450 – pancreatic cancer. darolutamide – metastatic hormone sensitive prostate cancer. mirvetuximab soravtansine – in ovarian cancer. KB-0742 – in MYC-amplified solid tumors. zandelisib – in relapsed/refractory follicular lymphoma. OP-1250 – in ≥4-line ER+/HER2-negative breast cancer.
Compendium (d) Compendium (f)